Myopic ophthalmopathy
Conditions
Interventions
Group 1: Patients undergoing intravitreal injections of panitumuamb.
Group 2: Patients in the control group with sham injections.
Sponsors
Ufa Eye Research Institute
Eligibility
Sex/Gender
All
Age
40 Years to 120 Years
Inclusion criteria
Inclusion criteria: - Age of 40+ years, - Axial length =26.5mm; - Myopic macular degeneration (category 3 (patchy atrophy) or higher). - Clear optic media to allow imaging of the macula and optic nerve head; - Progression of myopic maculopathy (increase in diffuse chorioretinal atrophy, enlargement of patchy atrophies, increase in the category of myopic macular degeneration, enlargement in parapapillary gamma/delta zone, increase in axial length, increase in myopic refractive error (after exclusion of lentogenic myopization), or myopia-associated reduction in best corrected visual acuity
Exclusion criteria
Exclusion criteria: - Previous vitreoretinal or retinal surgeries (except for peripheral retinal laser coagulation) - Previous intravitreal medical therapy with vascular endothelial growth factor (VEGF) inhibitors within the last three months before inclusion into the study; - Active subretinal choroidal neovascularization; - Subretinal or intraretinal edema in the macula; - Pregnancy; - Lack of reliable contraception unless menopause has occurred; - Known intolerance or hypersensitivity against panitumumab (Vectibix®) or its ingredients; - Participation in another clinical trial (parallel or within a cooling off period of a previous trial; - Missing possibility to understand and sign a written informed consent;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ocular axial length | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual acuity, morphology of the macula and optic nerve head | — |
Countries
Russia
Contacts
Public ContactMukharram Bikbov
Ufa Eye Research Institute
Outcome results
None listed